Parasites & Vectors

RESEARCH

Open Access

Evolving patterns of antimalarial drug resistance markers in symptomatic infections in Kenya, 2013–2022

John Magudha[1,4], Leonard Ndwiga[1], Mercy Y. Akinyi[1], Kevin Wamae[1], Victor Osoti[1], Regina Kandie[2], Rosebella Kiplagat[2], Kibor Keitany[2], Joel L. Bargul[4], Hoseah M. Akala[3] and L. Isabella Ochola-Oyier[1*]

Abstract

Background Ongoing antimalarial drug resistance surveillance is essential to guide effective treatment strategies. Historically, resistance to chloroquine and sulfadoxine-pyrimethamine (SP) has been associated with well-characterized mutations in the chloroquine resistance transporter (*Pfcrt*; K76T) and antifolate pathway genes, including dihydrofolate reductase (*Pfdhfr*; N51I, C59R, S108N) and dihydropteroate synthase (*Pfdhps;* A437G, K540E, A581G). Since the introduction of artemisinin-based combination therapies (ACTs), 13 mutations in the kelch 13 (PfK13) propeller domain have emerged as World Health Organization (WHO) validated markers of partial artemisinin resistance. This study aimed to characterize temporal trends in both established, *Pfcrt* and *Pfk13,* and less well-described potential markers, cysteine desulfurase (*Pfnfs)* and *Pfcoronin*, using febrile malaria samples collected across diverse regions of Kenya between 2013 and 2022.

Methods The temporal trend of these markers of resistance were assessed by screening archived *P. falciparum*-positive dried blood spots (DBS). A total of 1750 DBS samples were collected from therapeutic efficacy studies (TES) conducted across distinct malaria transmission settings in Kenya, including coastal Kenya (Kwale 2013, $n=350$; 2018, $n=150$), the lake endemic region of Western Kenya (Kisumu 2015, $n=314$; Busia 2016, $n=334$), and the highland epidemic region of western Kenya (Kisii 2017, $n=314$). Additional samples were obtained from an *hrp2* study conducted in Kisii in 2022, ($n=288$). Parasite genomic DNA was extracted using the Chelex-saponin method and confirmed by a *Pf*18S real-time polymerase chain reaction (RT-PCR). *Pfk13, Pfcrt, Pfnfs*, and *Pfcoronin* PCR amplicons were sequenced using capillary electrophoresis, Illumina Miseq or Oxford Nanopore (GridION) platforms.

Results The prevalence of *Pfcrt* mutations declined over time and no WHO-validated *Pfk13* mutations associated with artemisinin resistance were detected. However, synonymous substitutions at WHO-validated codons C469C and P553P were identified. In the *Pfcoronin* gene, nonsynonymous mutations distinct from those reported in West Africa were observed at high frequencies (> 75%). Notably, the *Pfnfs*-K65Q mutation, previously associated with reduced lumefantrine sensitivity in West Africa, was detected in more than 80% of the samples.

Conclusions Our findings reveal no WHO-validated *k13* mutations up until 2022 and confirm previous findings of a reduction in the *Pfcrt* resistance genotypes over time. This study underscores the importance of continued molecular surveillance and suggests that resistance may evolve through different pathways in East compared with West Africa and Southeast Asia.

*Correspondence:
L. Isabella Ochola-Oyier
Lioyier@kemri-wellcome.org
Full list of author information is available at the end of the article

Keywords *Plasmodium falciparum*, Malaria, Drug resistance, *Pfcrt*, *Pfk13*, *Pfnfs*, *Pfcoronin*, Molecular surveillance, Artemisinin, Kenya, Temporal trends, Antimalarial resistance

Background

Despite considerable progress in malaria control through preventive measures and effective antimalarial treatment, *Plasmodium falciparum* remains a major public health challenge, with an estimated 263 million cases reported globally in 2023 [1]. Efforts to reduce this burden continue to depend on three main pillars: vaccination, vector control, rapid case detection, and the use of effective antimalarials for treatment [2].

The World Health Organization (WHO) recommends the use of a combination of compounds with distinct modes of action for malaria treatment, ensuring effective cure rates to impede the development of resistance. Artemisinin-based combination therapies (ACTs) are the first-line treatment for uncomplicated *P. falciparum* malaria in all endemic countries [3]. ACTs integrate an artemisinin derivative with a non-artemisinin partner drug. Although the efficacy of ACT is dependent on both agents, the artemisinin is critical to reduce the bulk of parasite biomass during the first 3 days of treatment with the partner drug eliminating the remaining parasites [4].

The emergence of resistance to artemisinin and its derivatives in Southeast Asia, manifested as delayed parasite clearance following treatment with these drugs, is of great concern [5]. Historically, areas with low rates of mixed-strain transmission, particularly in Southeast Asia, have served as the initial focal points that exhibit resistance to antimalarial drugs [6]. Recent work attributed the artemisinin resistance phenotype found in Southeast Asia to mutations in PF3D7_1343700, which encodes a protein homologous to kelch proteins from other organisms [7]. Artemisinin-resistant parasites have been shown to harbor multiple mutations in the propeller domain of the Kelch 13 protein. Mutations in *P. falciparum* kelch 13 (*Pfk13*) gene, initially identified in Southeast Asia, including Y493H, R539T, I543T, and C580Y [7], have rarely been observed in Africa. However, alternative *Pfk13* mutations have been identified across eastern and central Africa, including G449A, C469Y, and R561H in Rwanda [8, 9]; C469Y, R561H, and A675V in Uganda [10]; R622I in Sudan, Eritrea, and Ethiopia [11, 12]; C469Y, P553L, and A675V in Kenya [13–15]; R561H and R622I in Tanzania [16–18]; and P441L, C469Y, and R561J in the Democratic Republic of Congo [19]. In Ethiopia [11, 20], Rwanda [8], Uganda [10, 21], and Tanzania [22], the mutations have also been associated with delayed parasite clearance, raising concerns about the potential of ACT failure across the region [23].

Additional markers linked to chloroquine resistance, the chloroquine resistance transporter (*Pfcrt*); lumefantrine tolerance, potentially cysteine desulfurase (*Pfnfs*) [24]; and artemisinin resistance, potentially coronin, have been identified [25]. Chloroquine was used as a first-line antimalarial until 1998 when it was retracted as a result of widespread reports of resistance in sub-Saharan Africa [26]. Chloroquine resistance was primarily attributed to the *Pfcrt* 76T mutation [27]. The cysteine desulfurase (*nfs*) K65 allele was implicated in lumefantrine resistance in West Africa [24], whereas mutations 50E, 100K, and 107V in *Pfcoronin* were associated with artemisinin resistance in Senegal [28].

In this study, we leveraged archived samples collected across multiple therapeutic efficacy studies (TES) to reconstruct the historical landscape of *P. falciparum* drug resistance in Kenya. The *Pfcrt* locus was included as a well-characterized marker to contextualize long-term trends, particularly the documented decline of mutant alleles over time [29, 30]. The novel markers *Pfnfs* and *Pfcoronin* were also examined to assess whether the mutations reported in West Africa are present in Kenyan parasite populations. Finally, the analysis of *Pfk13* provided temporal and spatial insights into emerging artemisinin resistance patterns among symptomatic cases.

Methods

Study area and sampling

This retrospective study utilized archived dried blood spot (DBS) samples originally collected during therapeutic efficacy studies (TES) conducted at four sites in Kenya: Kwale County (2013), Kisumu County (2015), Busia County (2016), and Kisii County (2017). Additionally, samples from a follow-up artemether-lumefantrine (AL) efficacy trial conducted in Kwale County in 2018 were included [31]. All parent studies received ethical approval from the Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit (SERU). Children aged between 6 months and 14 years seeking treatment at the outpatient departments of participating health facilities with signs of uncomplicated malaria were sampled. Eligible children for whom parental/guardian informed consent was obtained were randomized into a TES to receive dihydroartemisinin-piperaquine (DP) or artemether-lumefantrine (AL). The informed consent process included permission for long-term storage and future use of specimens for malaria-related molecular analyses. Participants were then required to report to the study clinic on days 1, 2, 3, 7, 14, 21, 28, and 42. Approximately 0.05 mL of blood from a

finger prick was collected and used to prepare thin and thick smears as well as to prepare dried blood spots (DBS). Slides were examined and stained with Giemsa under the microscope to detect the presence of malaria parasites and provide parasite density estimates as parasites per microlitre. In 2022, an *hrp2* study was conducted in Kisii County, Kenya, a highland malaria epidemic-prone region. This study was part of a broader cross-sectional study aimed at characterizing histidine rich protein (HRP) 2/3 gene deletions in patients of all ages presenting with uncomplicated malaria reporting at primary healthcare facilities across ten high and low malaria transmission counties: Nairobi, Kirinyaga, Homa Bay, Kilifi, Garissa, Kisumu, Kwale, Trans Nzoia, and Tana River. The study sites from which samples were obtained are shown in Fig. 1.

Detection of parasite positive samples by RT-PCR

Parasite DNA was extracted from 1750 DBS samples using the Chelex-saponin method, following the manufacturer's protocol. This was composed of 350 samples from Kwale (2013), 314 from Kisumu (2015), 334 from Busia (2016), 314 from Kisii (2017), 150 from Kwale (2018), and 288 from Kisii (2022). Briefly, samples were lysed with 0.5% (w/v) saponin in 1X phosphate-buffered saline (PBS) overnight. Following saponin aspiration, the discs were incubated in 1 mL 1X PBS at 4 °C for 30 min after which 150 µL of 6% (w/v) Chelex in nuclease-free water was added and incubated for 10 min at 97 °C. The samples were then centrifuged at 4000 × *g* for 5 min, and 120 µL of the DNA-containing solution was stored at −20 °C for downstream analysis.

The extracted DNA was screened for the presence of *Plasmodium falciparum* (*Pf*) using the TaqMan probe-based PCR assay targeting *P. falciparum* 18S rRNA gene, as described in Osoti et al. [32]. Briefly, 2.5 µL of each primer (10 pmol/µL), 0.625 µL of 18S probe (10 pmol/µL), 12.5 µL of 2X TaqMan universal PCR master mix, and 6.75 µL of sample or 3D7 control samples, with the remaining volume PCR clean water, was used. The reaction was done using the following qPCR cycling



Figure 1 Map of Kenya showing the study sites for the therapeutic efficacy studies (TES) and the HRP2 survey. TES were conducted in four counties: Kwale (2013 and 2018), Kisumu (2015), Busia (2016), and Kisii (2017). Additionally, an HRP2 study was carried out in Kisii in 2022

conditions: 50 °C for 2 min, 95 °C for 10 min, and then 45 cycles of 95 °C for 15 s and 95 °C for 1 min. Ct cutoff of ≥ 39 was taken as a negative sample.

PCR amplification and sequencing of antimalarial resistance-associated and candidate genes

Amplicons were generated from genomic DNA for the *Pfk13* gene from the *Pfhrp2* study and the *Pfcrt*, *Pfnfs*, and *Pfcoronin* genes from the TES conducted in Busia, Kisii, Kisumu, and Kwale counties (Table 2). PCR amplifications were performed using the Expand High Fidelity PCR System (Roche) and HotStarTaq Master Mix (Qiagen, Cat. No. 202602). All reactions were performed to a final volume of 10 µL, and each reaction mixture contained 200 µM dNTPs, 300 nM of each primer, 1X PCR buffer (containing 1.5 mM $MgCl_2$, 2.5 mM of $MgCl_2$ (buffer 2), 0.035U of Taq, and 0.7 µL of the template DNA. The cycling conditions of the four gene fragments were as follows: 94 °C for 2 min, 94 °C for 15 s, 30 cycles at annealing temperatures presented in Table 1 for each gene(X), 68 °C for 2 min, and a final extension of 7 min at 72 °C. The amplified PCR products were analyzed on 1.5% (w/v) agarose gel, purified using ExoSAP-IT® (Affymetrix, Santa Clara, CA) as per the manufacturer's instructions), and then sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit reaction mix (Applied Biosystems, USA) using 3730XL sequencer. The raw sequence data from both forward and reverse sequences were assembled into contigs using CLC Main Workbench. This method was utilized for these genes, as the loci of interest were known for coronin, *Pfcrt*, and *Pfnfs*, and for *Pfk13* to compare with Illumina, which can detect low frequency single nucleotide polymorphisms (SNPs).

Pfk13 drug resistance marker genotyping

Amplicons spanning the codon 425–720 of the Kelch 13 propeller domain (PF3D7_1347700) were generated using conventional PCR. Each 20 µL reaction contained 1 µL of template DNA (< 25 ng), 0.2 µL of Q5 High-Fidelity DNA Polymerase (0.02 U/µL, New England BioLabs), 1 µL (10 mM) forward primer, 1 µL (10 mM) reverse primer, 0.4 µL (10 mM) dNTPs (New England BioLabs), 4 µL (5X) Q5 reaction buffer (New England BioLabs), and 12.4 µL nuclease-free water. The following PCR cycling conditions were used: 98 °C for 30 s, followed by 30 cycles of 98 °C for 10 s, 60 °C for 30 s, 72 °C for 30 s, and final extension of 72 °C for 2 min. Successful PCR amplification was confirmed using 1% (w/v) agarose gels stained with RedSafe nucleic acid staining solution. PCR products were purified using 1X AMPure Beads (Beckman Coulter, USA). Purified PCR products were quantified with Qubit dsDNA HS Assay Kit. Thereafter, the PCR products were normalized to equal concentration of 1 ng each using nuclease-free water. Sequencing was performed with either Oxford Nanopore Technology (ONT), Illumina, or Capillary sequencing as presented in Table 2.

Table 2 Sequencing platforms used to genotype *P. falciparum* drug resistance gene amplicons from the different study sites

Study	Site(s)	Sequencing platform(s)	Gene(s) sequenced
TES	Busia, Kisii, Kisumu, Kwale	Capillary	coronin, nfs, crt
TES	Busia, Kisii, Kisumu, Kwale	Illumina	k13
TES	Busia, Kisii, Kisumu, Kwale	ONT	k13
HRP2	Kisii	Capillary and Illumina	k13

Amplicon library preparation and sequencing

Illumina library preparation was done using the Nextera XT (Illumina) and Kapa HyperPrep kits (Roche). Transposome was used to fragment and tag DNA with adapters. A limited-cycle PCR was used to add unique indices to each sample. Cleaning was done using 0.8X AMPure XP beads to select for fragments > 300 bp in size. Finally,

Table 1 List of primers used for capillary and amplicon sequencing

Gene	Amplicon size	Primers (5′–3′)	Annealing temp
Pfcrt	194	Forward-GGTGGAGGTTCTTGTCTTGG-3′	63
		Reverse-ATAAAGTTGTGAGTTTCGGATG-3′	
Pfnfs	600	Forward-CTTCAATTTTGTAATGAAATTTCTTC-3′	51
		Reverse-AGATTTGTTCGTGCATCCT-3′	
Coronin	849	Forward-ACATGTGGTATAGCTTGTAGTGCTGGAT-3′	58
		Reverse-AGAATTGAAATTATGGAGTTTAAAGA-3′	
Pfk13	886	Forward-GAAGCCTTGTTGAAAGAAGC	60
		Reverse-CGGAGTGACCAAATCTGG	

5.0 µL of each library was pooled and loaded on the Illumina MiSeq run.

ONT library preparation followed the protocol previously described by Adegbola et al. [33]. Briefly, purified amplicons were first end-repaired using NEBNext Ultra II End repair/dA-tailing Kit (New England BioLabs, USA), and 2 µL of the end-repaired product was used for barcode ligation with Native Barcodes (SQK-NBD114.96, Oxford Nanopore Technology, Oxford, UK) and NEBNext Blunt/TA Ligase Master Mix (New England BioLabs, USA). Barcoded amplicons were pooled and cleaned using 0.4X AMPure XP beads. Adapter ligation of the cleaned 50–100 ng library was done using the NEBNext Quick Ligation Module reagents (New England BioLabs, USA) and Adapter Mix II (Oxford Nanopore Technology, Oxford, UK). A final clean-up was performed using 125 µL of Short Fragment Buffer (Oxford Nanopore Technology, Oxford, UK) and the library was eluted in 15 µL Elution Buffer (ONT, Oxford, UK). The final library was normalized to 15–70 ng, loaded on a SpotON R9 flow cell and sequenced on the ONT GridION platform.

Sequence data analysis

Sequence data from genotyping of the three Sanger-sequenced drug resistance markers was analyzed using CLC Genomics Workbench v23.0. SeekDeep version 3.0.1 was used in analysis of the Illumina- [32] and ONT- [33] generated data. The paired consensus reads for each sample were trimmed and clustered to estimate the frequency of K13 mutations. The SNP frequencies were calculated using R version 4.2.1. Within-sample frequency was calculated by dividing the number of reads supporting the non-reference allele by the total number of reads per sample.

Results

Sequence data coverage

Following *Pfk13* gene amplifications, a total of 354 samples were successfully sequenced by Illumina, including 68 from Busia and 286 from Kisii. Additionally, 277 samples were successfully sequenced by ONT, comprising a different set of 43 samples from Busia, 94 from Kwale (2013 and 2018), and 140 from Kisumu. Illumina combined all the samples sequenced into one sequencing run, generating a total of 42 million reads, whereas the samples sequenced on ONT were distributed into three runs resulting in 21 million, 14 million, and 15 million reads. There was good read depth generated from the samples from Kisii, which also had the largest number of samples sequenced by Illumina (Fig. 2).

Analysis of Kisii HRP2 survey samples for k13 polymorphisms

A total of 288 samples were screened by 18S rRNA real-time PCR (RT-PCR) with 98/288 (34%) samples being positive with detectable levels of *Pf* DNA. Out of these, 90/98 and 92/98 samples had good-quality *Pfk13* data for Sanger and Illumina sequencing, respectively. Out of the 90 samples analyzed by Sanger sequencing, only 1 sample was found to harbor both a synonymous mutation (A627A) and a nonsynonymous mutation (S679T) within the k13 propeller domain. Illumina sequencing identified only the A627A and not the nonsynonymous mutation (S679T). Specifically, a total of 5 synonymous mutations were identified in 15/92 samples (16.3%) sequenced by Illumina platform (Table 3). The P553P mutation showed the highest prevalence, occurring in 8 of 92 samples, followed by C469C in 3 of 92 samples and A427A in 2 of 92 samples. The remaining synonymous mutations (G548G and A627A) were observed in one sample each. The G548G and A627A synonymous mutations had a > 98% within sample frequency (Additional file 1: Table S1). Illumina identified more low-frequency k13 alleles than capillary sequencing.

Prevalence of *k13* mutations in the TES samples

A total of 11 *Pfk13* mutations were identified, with no contribution from Kwale in the east of the country, since the parasite populations (from both 2013 and 2018) were 100% wild-type (Table 3). Only two nonsynonymous mutations were observed, A578S and S679T, at low frequencies. A single synonymous mutation (A427A) was identified in Kisumu in 2015 alongside the common nonsynonymous A578S mutation. The first observation of a synonymous mutation, C469C (a current WHO-validated artemisinin resistance associated codon) was in Busia in 2016 and its presence was observed and sustained in Kisii in 2017 and 2022. The other WHO-validated mutation codon, 553, also contained a synonymous mutation in Kisii in 2022. All the mutations were low frequency (< 5%) except the P553P synonymous mutation (Table 3).

Prevalence of other drug resistance mutations in the TES samples

A total of three genes, *Pfcrt*, *Pfnfs*, and *Pfcoronin*, were genotyped to determine the frequency of known single nucleotide polymorphisms and to identify any novel mutations across the four sites. The K76T mutations identified in the *Pfcrt* gene was highest in Busia 2016 at a frequency of 4.7%, followed by Nyando 2015 at 1.7%. There were no *Pfcrt* mutations identified in both Kisii (2017) and Kwale (2018). A number of mutations were



Figure 2 Distribution of k13 amplicon read depth across study sites and sequencing platforms. The median read counts for Illumina platform (left) were: 62,068 (Busia 2016), 94,791 (Kisii 2017), and 23,612 (Kisii 2022), while ONT platform (right) yielded median read counts of 45,248 (Kwale 2013), 26,925 (Kisumu 2015), 24,355 (Busia 2016), and 6835 (Kwale 2018)

Table 3 Temporal trends of Pfk13 mutations

Gene	*Pfk13* mutation frequencies, % [*n*]											
Codon	Sample size	A427A	C469C	R471R	G548G	P553P	A578S	A627A	G638G	V666V	S679T	N694N
Kwale 2013^{O}	57	0	0	0	0	0	0	0	0	0	0	0
Kisumu 2015^{O}	140	2.1 [3]	0	0	0	0	2.1 [3]	0	0	0	0	0
Busia 2016$^{O\&I}$	43^{O},72^{I}	0	1.4 [1]	0	0	0	1.4 [1]	0	0	0	0	0
Kisii 2017^{I}	286	0	0.7 [2]	0.3 [1]	0	0	0.3 [1]	0	0.3 [1]	1 [3]	0	0.7 [2]
Kwale 2018^{O}	37	0	0	0	0	0	0	0	0	0	0	0
Kisii 2022^{I}	92	2.17 [2]	3.3 [3]	0	1.1 [1]	8.7 [8]	0	1.1 [1]	0	0	0	0
Kisii 2022^{C}	90	0	0	0	0	0	0	1.1 [1]	0	0	1.1 [1]	0

% indicates the proportion of isolates carrying each mutation, and the values in brackets [] represent the number of samples. "0" indicates that no mutations were detected at that codon. Codon shown in bold denote a WHO-validated artemisinin resistance mutation (e.g., C469Y and P553L). Sequencing platforms are indicated as follows: O: ONT GridION, I: Illumina MiSeq, and C: capillary electrophoresis (Sanger sequencing)

identified in the *Pfnfs* gene including the 65Q allele. Only one mutation, 183G, in the *coronin* gene, was identified in all four sites (Table 4).

Discussion

The molecular surveillance from symptomatic patient samples identified synonymous *Pfk13* mutations, C469C and P553P, codons where nonsynonymous variants associated with artemisinin resistance (e.g., C469Y and P553L) are now increasingly being reported in the East Africa [10, 13, 14, 34, 35]. Recent studies from Kenya have reported nonsynonymous mutations emerging at these same loci, such as C469Y in symptomatic and asymptomatic populations and P553L in asymptomatic populations, which are associated with artemisinin resistance [13, 14]. This pattern raises the possibility

Table 4 The frequency of mutations in CRT, NFS, and coronin by capillary electrophoresis

Gene	crt % [*n*]				Coronin % [*n*]	nfs % [*n*]						
Nucleotide	*G222T*	*T225A*	*A227C*	*T248A*	*A547G*	*GI85A*	*A193C*	*A200G*	*A304G*	*C328G*	*G359T*	*G390C*
Codon	*M74I*	*N75E*	*K76T*	–	S183G	S62N	K65Q	E67G	N102D	Q110E	S120I	E130D
Kisumu 2015	1.7 [3]	1.7 [3]	1.7 [3]	–	88.5 [46]	88 [66]	82.7 [62]	84 [63]	1.3 [1]	14.7 [11]	42.7 [32]	20 [15]
Busia 2016	2.7 [4]	3.3 [5]	4.7 [7]	–	75 [24]	85.4 [41]	89.6 [43]	89.6 [43]	–	–	20.5 [8]	6.1 [2]
Kisii 2017	0 [0]	0 [0]	0 [0]	1.2 [1]	69.7 [23]	86.9 [119]	82.7 [115]	83.5 [116]	0.7 [1]	12.2 [18]	38.9 [58]	24.5 [37]
Kwale 2018	0 [0]	0 [0]	0 [0]	–	80 [32]	85.4 [76]	86.9 [73]	74.4 [67]	0 [0]	8.9[8]	35.6 [32]	27.8 [25]

The total number of samples sequenced for crt (Kisumu, $n=179$; Busia, $n=153$; Kisii, $n=84$; Kwale, $n=89$), for coronin (Kisumu, $n=52$; Busia, $n=52$; Kisii, $n=34$; Kwale, $n=87$), and for nfs (Kisumu, $n=74$; Busia, $n=51$; Kisii, $n=160$; Kwale, $n=89$)

that drug-resistant *P. falciparum* parasites could emerge through random synonymous substitutions, which subsequently evolve into nonsynonymous mutations that are advantageous under continued drug pressure. Previous data have shown that as the mutations rise in high frequency due to positive selection, mutant-only infections are observed, as is the case for DHFR (codons 108 and 51) and DHPS (codons 437 and 540) mutations [36].

This initial emergence of *Pfk13* mutations as synonymous mutations that may generate the basic working material for continued natural selection suggests early changes that provide a warning of a changing gene over time. Although synonymous mutations have traditionally been regarded as functionally neutral, emerging evidence suggests they may play a more active role in shaping evolutionary trajectories [37]. Their persistence can result in resistance-conferring variants. Additionally, the mutations are observed at low frequency in a few samples in mixed genotype infections. Forman and Coller proposed that synonymous mutations may facilitate evolutionary access to previously unfavorable amino acid changes by modifying codon usage.

Interestingly, no *Pfk13* mutations were observed in the eastern part of the country, which could be attributed to the low sample size and the potential lower sensitivity of the ONT platform to detect low frequency variants on the basis of the lower read coverage. Nevertheless, *Pfk13* mutations are emerging in Western Kenya, further corroborated by previous publications [13–15], highlighting this area as the region to watch and intensifying surveillance efforts for *k13* mutations and potential artemisinin treatment failure. The recent publications of the presence of validated *Pfk13* mutations raise the urgency of a TES evaluation to assess the clinical relevance of these mutations in Kenya.

The temporal patterns observed in *Pfcrt* provide further evidence of the shift in directional selection toward a fully wild-type genotype. The mutant 76T allele declined steadily and reached zero in Kisii and Kwale after 2016, consistent with previous findings from Kilifi and Kisumu following the withdrawal of chloroquine pressure [30, 38]. In contrast, no clear temporal trends were observed for the putative markers *Pfnfs* and *Pfcoronin*, whose allele frequencies remained relatively high but fluctuated across sites and years. These patterns differ from those reported in parts of West Africa, where *Pfnfs* variants have shown increasing frequency over time [24] and a completely different mutation from what has been published previously for *Pfcoronin*, codon 183 [25, 28]. Although both genes have been proposed as potential markers of lumefantrine and artemisinin tolerance in West Africa, our findings suggest that they are not currently under strong selection in East Africa. Furthermore, the Kenya parasite population are now predominantly wildtype at the PfCRT locus (CVMNK) compared with parasites from West Africa, where there is still a high prevalence of the resistant haplotype CVIET [39, 40]. This is not surprising since the drug pressure in East and West Africa is different, generating parasites with a different genetic background [24].

The potential limitation in this study is the use of different sequencing platforms. The markedly lower number of *k13* SNPs detected in the ONT-sequenced samples, such as the absence of mutations in Kwale 2013 and only the single mutation observed in Kisumu 2015, may in part reflect the well-recognized differences in platform characteristics, including ONT's lower base-calling accuracy relative to Illumina. Both platforms generated sufficient read coverage to call *Pfk13* variants at the targeted loci, though Illumina's higher read depths and greater base-calling precision likely improved its ability to resolve low-frequency polymorphisms. However, recent advances in ONT flow-cell chemistry and base-calling algorithms continue to enhance its performance, and its portability, lower cost, and real-time data generation make it an attractive tool for surveillance applications [41]. Sanger sequencing was easier to conduct and analyze, however, it primarily detects the dominant genotypes and high-frequency mixed genotypes; rare variants were difficult

to define. Though the platforms were different, the SNP frequency data generated allowed for comparisons of the same genetic loci across samples from different regions, with the caveat that a lower sample size impacts read coverage.

Conclusions

Taken together, this retrospective analysis provides a rare temporal and geographical perspective on the evolution of *P. falciparum Pfk13* polymorphisms in Western and Coastal Kenya between 2013 and 2022, made possible by harmonizing data across multiple therapeutic efficacy studies. The *Pfcrt* temporal trends provided confidence in the observed data for the other genetic markers. The presence of the synonymous C469C and P553P mutations in Kisii, alongside the contrasting prevalence patterns of *Pfnfs* and *Pfcoronin* between East and West Africa, highlights the heterogeneous molecular pathways through which artemisinin resistance may emerge across the continent. Additionally, it underscores the importance of continuous, national molecular surveillance to detect early signals of evolving resistance and to guide timely public health interventions.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13071-026-07280-w.

Additional file 1: Table S1. Within sample non-referencek13 allele frequencies in samples collected from the Kisii hrp2/3 study.

Acknowledgements

We are grateful to the study participants and their guardians, as well as the field and laboratory teams involved in this work. We also thank the National Malaria Control Programme (NMCP) for coordinating the Therapeutic Efficacy Studies (TES). We acknowledge the contribution of Emmanuel Asiimwe in generating the map. All laboratory experiments were carried out at the KEMRI–Wellcome Trust Research Programme laboratories.

Author contributions

LIOO secured funding, conceived the study, and designed the experiments. JM and LN performed the experiments. JM, LN, MA, KW, and LIOO analyzed the data. LIOO, RK, RK2, KK, and HA supervised fieldwork and were responsible for sample acquisition. JM, LN, and LIOO drafted the initial manuscript. All authors (JM, LN, MA, KW, VO, RK, RK2, KK, JL, HA, and LIOO) contributed to data interpretation, critically reviewed the manuscript, and approved the final version.

Funding

This work was supported by funds from the Bill & Melinda Gates Foundation (BMGF) (grant no.: INV-036442).

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate

The approval for conducting these studies was obtained from the Kenya Medical Research Institute/Scientific and Ethics Review Unit (KEMRI/SERU). All study participants (or their parents/guardians) gave written informed consent for participation, including permission for long-term storage of their specimen for use in malaria-related molecular analyses.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

[1]Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya. [2]Division of National Malaria Programme, Ministry of Health, Nairobi, Kenya. [3]Walter Reed Army Institute of Research - Africa (WRAIR-A), Kenya Medical Research Institute (KEMRI), Kisumu, Kenya. [4]Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology (JKUAT), P.O. Box, 62000, Nairobi 00200, Kenya.

Received: 15 September 2025 Accepted: 21 January 2026
Published online: 06 February 2026

References

1. World Malaria Report 2023. World Health Organization; 2024.
2. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U et al. The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. Nature. 2015;526:207.
3. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77:181–92.
4. White NJ. Antimalarial drugesistance. J Clin Invest. 2004;113:1084–92.
5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J et al. Artemisinin resistance in *Plasmodium falciparum* malaria. N Engl J Med. 2009;361:455.
6. Menard D, Dondorp A. Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med. 2017;7:a025619.
7. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N et al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. Nature. 2014;505:50–5.
8. Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N et al . Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602–8.
9. Straimer J, Gandhi P, Renner KC, Schmitt EK. High prevalence of *Plasmodium falciparum* K13 mutations in Rwanda is associated with slow parasite clearance after treatment with Artemether-Lumefantrine. J Infect Dis. 2022;225:1411–4.
10. Awor P, Coppée R, Khim N, Rondepierre L, Roesch C, Khean C et al. Indigenous emergence and spread of kelch13 C469Y artemisinin-resistant *Plasmodium falciparum* in Uganda. Antimicrob Agents Chemother. 2024;68:e0165923.
11. Mihreteab S, Platon L, Berhane A, Stokes BH, Warsame M, Campagne P et al. Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea. N Engl J Med. 2023;389:1191–202.
12. Bayih AG, Getnet G, Alemu A, Getie S, Mohon AN, Pillai DR. A unique *Plasmodium falciparum* K13 gene mutation in Northwest Ethiopia. Am J Trop Med Hyg. 2016;94:132–5.
13. Osoti V, Wamae K, Ndwiga L, Gichuki PM, Okoyo C, Kepha S et al. Detection of low frequency artemisinin resistance mutations, C469Y, P553L and A675V, and fixed antifolate resistance mutations in asymptomatic primary school children in Kenya. BMC Infect Dis. 2025;25:1–10.
14. Makau M, Kanoi BN, Mgawe C, Maina M, Bitshi M, Too EK et al. Presence of *Plasmodium falciparum* strains with artemisinin-resistant K13 mutation C469Y in Busia County, Western Kenya. Trop Med Health. 2024;52:72.

15. Jeang B, Zhong D, Lee MC, Atieli H, Yewhalaw D, Yan G. Molecular surveillance of Kelch 13 polymorphisms in *Plasmodium falciparum* isolates from Kenya and Ethiopia. Malar J. 2024;23:36.
16. Juliano JJ, Giesbrecht DJ, Simkin A, Fola AA, Lyimo BM, Pereus D et al. Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. medRxiv. 2023; 11.07.23298207
17. Bwire GM, Ngasala B, Mikomangwa WP, Kilonzi M, Kamuhabwa AAR. Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. Sci Rep. 2020;10:3500.
18. Wernsman Young N, Gashema P, Giesbrecht D, Munyaneza T, Maisha F, Mwebembezi F et al. High frequency of artemisinin partial resistance mutations in the Great Lakes Region revealed through rapid pooled deep sequencing. J Infect Dis. 2025;231:269–80.
19. Mesia Kahunu G, Wellmann Thomsen S, Wellmann Thomsen L, Mavoko HM, Mulopo PM et al. Identification of the PfK13 mutations R561H and P441L in the Democratic Republic of Congo. Int J Infect Dis. 2024;139:41–9.
20. Fola AA, Feleke SM, Mohammed H, Brhane BG, Hennelly CM, Assefa A et al. Plasmodium falciparum resistance to artemisinin and diagnostics have emerged in Ethiopia. Nat Microbiol. 2023;8:1911–9.
21. Tumwebaze PK, Conrad MD, Okitwi M, Orena S, Byaruhanga O, Katairo T et al. Decreased susceptibility of *Plasmodium falciparum* to both dihydroartemisinin and lumefantrine in northern Uganda. Nat Commun. 2022;13:1–12.
22. Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD et al. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis. 2024;24:1225–33.
23. Schmedes SE, Patel D, Dhal S, Kelley J, Svigel SS, Dimbu PR et al. *Plasmodium falciparum* kelch 13 mutations, 9 countries in Africa, 2014–2018. Emerg Infect Dis. 2021;27:1902.
24. Amambua-Ngwa A, Jeffries D, Amato R, Worwui A, Karim M, Ceesay S et al. Consistent signatures of selection from genomic analysis of pairs of temporal and spatial *Plasmodium falciparum* populations from The Gambia. Sci Rep. 2018;8:9687.
25. Demas AR, Sharma AI, Wong W, Early AM, Redmond S, Bopp S et al. Mutations in *Plasmodium falciparum* actin-binding protein coronin confer reduced artemisinin susceptibility. Proc Natl Acad Sci U S A. 2018;115:12799–804.
26. Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health. 2000;5:755–64.
27. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT et al. Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861–71.
28. Delandre O, Gendrot M, Fonta I, Mosnier J, Benoit N, Amalvict R et al. Prevalence of mutations in the pfcoronin gene and association with ex vivo susceptibility to common quinoline drugs against *Plasmodium falciparum*. Pharmaceutics. 2021;13:1273.
29. Okombo J, Kamau AW, Marsh K, Sutherland CJ, Ochola-Oyier LI. Temporal-rends in prevalence of *Plasmodium falciparum* drugesistance alleles overwo decades of changing antimalarial policy in coastal Kenya. Int J Parasitol Drugs Drug Resist. 2014;4:152–63.
30. Wamae K, Okanda D, Ndwiga L, Osoti V, Kimenyi KM, Abdi AI et al. No evidence of Plasmodium falciparum k13 artemisinin resistance-conferring mutations over a 24-year analysis in Coastal Kenya but a near complete reversion to chloroquine-sensitive parasites. Antimicrob Agents Chemother. 2019;63:e01067-19.
31. Nderu D, Kimani F, Karanja E, Thiong'o K, Akinyi M, Too E et al. Genetic diversity and population structure of *Plasmodium falciparum* in Kenyan-Ugandan border areas. Trop Med Int Health. 2019;24:647–56.
32. Osoti V, Akinyi M, Wamae K, Kimenyi KM, de Laurent Z, Ndwiga L et al. Targeted amplicon deep sequencing for monitoring antimalarial resistance markers in Western Kenya. Antimicrob Agents Chemother. 2022;66:e0194521.
33. Adegbola AJ, Ndwiga L, Wamae K, Osoti V, Bolaji OO, Bejon P et al. ONT sequencing identifies a high prevalence of crt sensitive, triple mutant dhfr and single mutant dhps parasites within an ANC population in Nigeria. Front Genet. 2024;15:1470156.
34. Ogwang R, Osoti V, Wamae K, Ndwiga L, Muteru K, Ningwa A et al. A retrospective analysis of *P. falciparum* drug resistance markers detects an early (2016/17) high prevalence of the k13 C469Y mutation in asymptomatic infections in Northern Uganda. Antimicrob Agents Chemother. 2024;68:e0157623.
35. Osoti V, Wamae K, Musau MM, Magudha JB, Ndwiga L, Gichuki PM et al. Serial cross-sectional school surveys identifies C469Y, P553L, R561H and A675V kelch 13 mutations associated with artemisinin resistance in Western Kenya. Sci Rep. 2025;15:38303.
36. Matondo SI, Temba GS, Kavishe AA, Kauki JS, Kalinga A, Van Zwetselaar M et al. High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania. Malar J. 2014;13:1–7.
37. Sinha I, Woodrow CJ. Forces acting on codon bias in malaria parasites. Sci Rep. 2018;8:15984.
38. Achieng AO, Muiruri P, Ingasia LA, Opot BH, Juma DW, Yeda R et al. Temporal trends in prevalence of *Plasmodium falciparum* molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya. Int J Parasitol Drugs Drug Resist. 2015;5:92–9.
39. Ndiaye M, Faye B, Tine R, Ndiaye JL, Lo A, Abiola A et al. Assessment of the molecular marker of *Plasmodium falciparum* chloroquine resistance (Pfcrt) in Senegal after several years of chloroquine withdrawal. Am J Trop Med Hyg. 2012;87:640–5.
40. Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, Targett G et al. Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian *Plasmodium falciparum* imply reduced fitness of chloroquine-resistant parasites. J Infect Dis. 2007;196:1613–9.
41. Kunasol C, Dondorp AM, Batty EM, Nakhonsri V, Sinjanakhom P, Day NPJ et al. Comparative analysis of targeted next-generation sequencing for *Plasmodium falciparum* drug resistance markers. Sci Rep. 2022;12:1–10.

Publisher's Note